Bharat Book Bureau

For a number of years the European and Asian cellular phone industries have regarded themselves advanced from the US market, however, times are changing. With the launch of 3G services now starting to take place by network operators around the world, the US cellular industry is proving that it’s fast catching up.

The competitive situation in the US market and a slowness to license new spectrum has forced the biggest mobile operators to speed up the deployments of high-speed data services within their existing bands initially allocated for the PCS systems. With some of the key operators already launching 3G services in key markets, the US cellular industry is proving that, yet again, it’s not taking its future lightly.

Do you know what the 3G and wireless data strategy and plans of the key players are in the US market?
How will this affect your company’s future?
How can you make the most of the potential opportunities that will arise?

A new report published by it’s, “US 3G and wireless data services: market analysis and forecasts 2005-2010″, provides American, European and Asian companies with a thorough overall picture of what is happening in with US wireless data market. The report discusses network infrastructure deployment, and provides an in-depth focus on the country’s biggest mobile operators and their expected 3G strategies. Special attention is paid to the 3G standards types, revenue models, mobile data services, and thorough analysis of future developments in the US mobile telecoms market is provided along with total cellular subscriber and technology growth forecasts through to 2010.

With data expected to account for nearly 30 percent of total service revenues in the future, as an American company, are you making the most of the new trends of usage of data services on cell phones? Can your products further maximise their potential in the US cellular data marketplace?

For European and Asian companies, are you looking to get into the US cellular data market? The report provides key insight into this highly lucrative marketplace and offers an understanding of what services are currently being adopted.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44654
_______________________________________________________________

Wouldn’t it be great if you could answer these 3 questions everytime?, Will a drug be successful?, Will a drug make any money?, Is it worth investing in a drugs’ further development?, In these days of thin pipelines and revenues consolidating into a few products there is high pressure your company’s product managers to be sure that their next product, if not a blockbuster, is at least a winner. However, you will be fully aware that through Pharmacoeconomics, we can go some way to predict the future success of your drug!

But questions still remain

Are Pharmacoeconomics any good?
Do Pharmacoeconomics work?
it’s’s brand new report, answers these questions for you. This new report examines the link between this new developmental tool, the financial success of drug and how decision makers are increasingly using Pharmacoeconomics to make their drug purchases - are you using Pharmacoeconomics successfully?

Currently there are 4 economic factors in a pharmacoeconomic evaluation :

Cost minimisation
Cost effectiveness analysis (CEA)
Cost benefit analysis (CBA)
Cost utility analysis (CUA)
it’s’s Pharmacoeconomics and Success in the Marketplace report, examines these steps and points out their usefulness in a drugs’ commercial viability and market positioning.

The report also tackles crucial issues such as :

Formulary decisions
The current effective structure of Pharmacoeconomics
Data problems in implementing and succeeding in Pharmacoeconomics
The influence of Pharmacoeconomics in the pharmaceutical R&D sector
Global Pharmacoeconomic practice from the major industry players

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44655
_______________________________________________________________

Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 13.0% to 2009.it’s’s latest report, ” The Global Ophthalmic Pharmaceutical Market 2004-2009 ” , explains just how this market will experience growth over the medium term future.

The world market is currently valued at $7.25bn and revenues are forecasts to rise to over $14bn in 2009. Do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what stratergies can be used to maxmise profits from the drivers and restraints? Ensure your organisation is successful in this market by reserving your copy of it’s’s report today.

According to the findings of the new 170+page report, it’s reveals that Glaucoma therapies are set to dominate the market over the forecast period (2002-2009), accounting for almost 40% of market revenues by 2009. Indeed, 2004 saw the first blockbuster drug of the market, used to treat glaucoma.

Find out who are the major companies involved in the ophthalmic world market today and in the future. And what R&D opportunities exist for ‘new-comers’ to the ophthalmic pharmaceutical market.

In the process of providing a thorough evaluation of the market, the it’s Ophthalmics report focuses on the major therapeutic areas of the market:
Glaucoma
AMD
Ocular Allergies
Dry Eye Syndrome
Ocular Infections
Ocular Inflammation
Do you know what the market values of these major therapeutic areas of the ophthalmic world market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC ophthalmic drugs by disease and product type. The study also assess’s the challenges faced by ophthalmic companies, and what exciting market opportunites exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?

This report features over 50 tables, 30 graphs and charts, news, insights, the latest developments and an in depth survey of the ophthalmics market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company ‘the edge’ on your competitiors. You can not afford to be without this latest report from it’s.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44656
_______________________________________________________________

Cardiovascular has been the leading therapeutic category for over two decades and is set to continue its pace of expansion and dominance over the global drugs market. The cardiovascular market has expanded from a value of $60 billion in 1997 to $351.8 billion in 2003. With new drugs in the pipeline, competition in the cardiovascular market has never been greater. Ensure your organisation is successful in this market by reserving your copy of it’s’s annual Cardiovascular Report, today.

The principle aims of cardiovascular therapies are to reduce morbidity and mortality from heart attacks, strokes and other blood vessel related disease. 17 million deaths occur globally each year due to cardiac related problems. Cardiovascular is the largest therapy area in the global healthcare market, the statin market alone has a world market value of $22 billion.

This report is arranged to provide you with an in-depth knowledge of the cardiovascular drugs market, accompanied by analysis and forecasts by product type and application.

WHY YOU NEED TO BUY THIS REPORT TODAY :

• Cardiovascular disease is the number one cause of death & is increasing demand for effective treatments
• This 3rd annual edition updates you on the key areas of pharmaceutical R&D
• Identify the level of competition & major players in the cardiovascular therapy market
• Guide to the most common types of heart disease, their drug types, & emerging blockbusters
• Latest guidelines and clinical protocols that affect cardiovascular drug prescriptions

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44657
_______________________________________________________________

The content consumption paradigm of mobile phones is shifting away from pure voice applications to personalised non-voice applications. Personalised ringtones and logos have experienced widespread popularity: web-sites such as Yourmobile.com have sold in excess of 75 million ringtones and 10 million logos in over 85 countries. Phone covers have become a mark of Nokia’s successful brand.
One survey revealed that 21 per cent of industry experts believe that personalisation will be responsible for reducing customer churn.

While voice ARPU has been steadily decreasing at a pace of around $5 a year, contribution from mobile data applications is being felt by an increasing number of operators around the world. With the recent and forthcoming launches of content such as personalised location and transaction-based applications, one should see ARPU levels pass the $50 mark by the end of 2003 in many countries that have deployed these facilities.

This report looks at the impact and potential of a range of mobile phone personalisation facilities including:

Ringtones
Logos
Celebrity Voice-mail Messages
Handsets
Handset facias
Personalised Location Based Services (e.g. targeted navigational and advertising services)
It shows that mobile phone personalisation applications are evolving quickly and can make significant contributions to revenue for both mobile phone operators and content providers. If you want to know exactly how the various forms of mobile phone personalisation can be exploited and what pitfalls need to be avoided - then you need to read this report immediately.
This report answers the following questions:

Which target segments are responsive to personalisation?
What various forms of electronic personalisation are available?
Which vendors have responded to the need of electronic personalisation?
What are the new developments in electronic personalisation?
How is the market for electronic personalisation developing?
How is the market for handset personalisation developing?
What role does branding have in handset personalisation?
What personalisation features can location-based services offer?
What are the problematic issues surrounding location based services?
What are the new developments in personalisation?
This report is ideal for:
Handset manufacturers
Operators
Application Developers
Software Developers
Vendors
Mobile entertainment developers
Portals
Network Manufacturers
Marketing Companies

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44658
_______________________________________________________________

According to indepth analysis from Dr Ray Scraggs, Senior Pharmaceutical Industry Analyst with It the total value of the world market for antifungal medication, topical as well as systemic, was worth in 2003 nearly $6 billion. The report entitles The World Market for Antifungal Therapies 2004-2009 divides the total market into:

Systemic :

Topical OTC and Prescription
This is one of the few reports of this type on the market that attempts an analyses of both the systemic and topical markets.

Further the systemic market is subdivided into analyses that includes :
Azoles
Polyenes
Pyrimidines
Allylamines
Echinodians

According to Dr Scraggs the total market will see a growth rate decline with an average growth rate (AAGR) from 2002-2009 of only 39.1 per cent, revenues by 2009 will be approaching $8 billion. Systemic antifungals, not surprisingly dominate this market with a 60 per cent market share. This is a market you must become successful in.  There is a significant unmet need in this market because the present portfolio of treatments interact unfavourably with other medications, have resistance problems, low spectrum of activity, are fungistatic as opposed to fungicidal and are often toxic. The company that can arrive at a new class of drug that can overcome all these limitations will be guaranteed high profits.

Key Questions Answered in this Report :

Total revenues and growth rates for each market segment from 2002-2009
A list of the important drivers and restraints
Incisive market predictions for each segment and individual drug type
A market share analysis of each segment
New products and new developments
A review of the latest innovations in antifungal vaccine discovery
Analysis of market trends

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44659
_______________________________________________________________

The world vaccine market, once characterized by slow growth, has seen increased sales as a result of new paediatric vaccines and the burgeoning influenza vaccine markets in the U.S. and Europe. You should be taking advantage of this growth NOW!!. The adult market for vaccines is predicted to grow by 26.3 per cent in 2004, but what will it be in 2007 - only It’s unique report can tell you today.

In 2003 the world vaccine market is valued at over $5 billion, shouldn’t you be claiming an increased share of this market immediately.

Paediatric vaccines still hold the largest share of the overall market, but influenza and hepatitis vaccine sales have grown significantly over the past few years. Paediatric vaccines markets are growing at a slower rate than the adult market and you need to position your company correctly to ensure your continued success.

A large number of therapeutic vaccines under development prove to make the vaccine market an interesting and dynamic one over the next five years. Therapeutic vaccines are currently being tested against cancer and are approaching approval.

The Therapeutic and Prophylactic Vaccine Market 2003 provides in-depth analysis of the vaccine market, presents key findings that are driving the market, and contains up-to-date information regarding vital clinical trials, sales figures, and profiles of key vaccine companies.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44660
_______________________________________________________________

The combined value of the women’s reproductive health pharmaceutical market is currently over $20 billion. A positive growth rate of 8 per cent is expected per annum for the next five years, according to It Publishing of London. An expanded variety of contraceptive choices for women is driving growth, as is continued growth in the gonadotrophins class for infertility.

Negative press regarding the side effects associated with hormone replacement therapy (HRT) has slowed this market down slightly, leaving a vaccum of market share for other osteoporosis therapies. HRT will, however, rebound during the forecast period and re-achieve strong growth.

Women’s Reproductive Health 2004 is arranged to provide an overview of this complex market. Specific attention is given to the following areas:
Contraception
Infertility
Osteoporosis/Menopause
Analysis and financial forecasts in these markets take into account many factors including:
Consumer preference statistics
Product differentiation
New indications
Patent expirations
Generic competition
The Women’s Health Institute HRT Study
Emerging markets, eg. Japan
Detailed financial information and forecasting is also provided for each chapter including in-depth coverage of drugs in the infertility and osteoporosis drug markets such as:
Gonadotrophins
Bisphosphonates
Selective estrogen receptor modulators
GnRH Antagonists
Hormone replacement therapy
Detailed product differentiation and financial analysis is presented for the following contraceptive products:
Hormonal contraceptives
Intra-uterine devices
Transdermal patches
Depot contraceptives
Emergency contraception

Analysis includes the use of charts and graphs measuring product growth and trends within the women’s reproductive health marketplace. Company-specific information, including sales figures, drug pipeline status, and research and development trends is provided throughout the report. Five-year financial forecasts are also provided

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44661
_______________________________________________________________

One of the major problems in medical pharmacology is that a drug will not function to the same degree of efficacy in all patients. Often drugs will only exert the desired therapeutic effect in perhaps 30-70 per cent of patients. Anti-depressants, for example, are notorious for being successful in only 30 per cent of cases; the other 70 per cent are described as non-responders.
Furthermore drugs may function as predicted in one population of patients whilst in others it may lead to an adverse drug reaction (ADR). In the US it is estimated that over 2 million people are hospitalised and 100,000 die each year from ADR.

The reason for this differential of action is due to a person’s specific genetic make up which allows for a difference in how a drug is metabolised. The new discipline of pharmacogenomics investigated this all too important interaction between a putative pharmacological agent and persons genome. The underlying aim of pharmacogenomics would be to tailor a drug to a person’s genes, ushering in the era of personalized medicine.

The development of pharmacogenomics as a routine part of drug discovery will generate large and sustainable revenues for the drug industry - BUT HOW MUCH? Find out by reading this exclusive report.

There are other aspects to pharmacogenomics which includes the technical part of this new discipline: such as
* Bioinformatics
* DNA Microarrays

It will provide a detailed analyses of these markets including, revenues, growth rates, companies involved and new developments.

Complete with tables, news, insights, the latest developments and a complete survey of the pharmacogenomics market and research arena. Pharmacogenomics will most likely become the dominant drug discovery method in years to come and you and your organisation should be part of it.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44662
_______________________________________________________________

Broadband over Power Lines, also known as the “third wire” for deliveringbroadband communications to users, has been gaining traction on a globalbasis. Since, more than 100 trials in 40 different countries worldwide haveconfirmed the viability of BPL technology, and It sees thetechnology building momentum. Find out what market impact BPL will have bybuying this latest It report, “Broadband over Power line:Challenging existing broadband dynamics”.

One of the advantages offered by BPL is that the technology will helpstimulate new competitive market dynamics by introducing a new means ofbroadband access that does not require the building of an entirely newinfrastructure.

Questions answered in this report include:

What is the opportunity for BPL and where do the key markets lie?
What business models exist for BPL service providers?
What lessons can be learned from global BPL trials and deployments?
What threat does BPL pose to traditional fixed-line broadband networks?
What kinds of services and applications does BPL enable?
How does BPL compare with rival technologies in terms of price, cost and performance?

BPL has been hampered by concerns over interference and the lack ofstandards necessary to drive it forward. But recent developments point tothese problems being resolved. It believes the questions ofBPL-caused RF interference have recently begun to be answeredsatisfactorily. Further, movements by various global standards bodiespromises to boost the market.

This report will also tell you:

How is BPL standardisation progressing
What the regulatory environment is regarding BPL around the world
What the evolution towards next-generation BPL promise to deliver
The main market players and their strategies
What are the market drivers and barriers
Where the most activity is to be seen

The ubiquity of electric power lines as the means of providing access to theInternet is of particular benefit in rural areas, where the biggest promiselies for BPL. But It warns that unless governments are willing tosubsidise the substantial infrastructure costs required to enable a BPLsystem, the technology of providing broadband access over power lines maynot be economically viable in these areas.

In urban areas, BPL’s timing is critical, because it must compete in a verycompetitive marketplace, one in which legacy players have not onlyestablished a firm foothold, but are beginning to offer triple-playservices, giving them differentiation and a competitive advantage. For BPLto succeed, it needs either a significant difference in service or pricebetween BPL and existing broadband methods.

This latest 70+ page report from It examines BPL both as astand-alone technology and as a competitive entry into the broadbandmarketplace. Interference is comprehensively detailed and analysed in thisreport, as are other issues surrounding BPL.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44667
_______________________________________________________________